Secondly, TRIM21 was found to inhibit Th1/Th17 differentiation in the intestinal mucosa by ubiquitinating IRF3 in CD4+T cells, thus playing an anti-inflammatory role in the pathogenesis of IBD (87). Here, CD4 is linked to inflammatory bowel disease.